Pharmacological explanations for cerivastatin associated rhabdomyolysis;Klinisch pharmakologische erklärungsmodelle der cerivastatin-assoziierten rhabdomyolyse

Wiener Medizinische Wochenschrift

Volumn 153, Issue 11-12, 2003, Pages 250-254

  Zeitlinger, Markus ^a   Müller, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adverse events; Cerivastatin; Rhabdomyolysis; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

APOPTOSIS; ARTICLE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG SAFETY; HUMAN; IC 50; MORBIDITY; RHABDOMYOLYSIS; SIDE EFFECT;

EID: 0037965193     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1563-258x.2003.03029.x     Document Type: Article

References (45)

1. Aberg F, Appelkvist EL, Broijersen A, Eriksson M, Angelin B, Hjemdahl P, Dallner G: Gemfibrozil-induced decrease in serum ubiquinone and alpha- and gamma-tocopherol levels in men with combined hyperlipidaemia. Eur J Clin Invest 1998;28:235-242.
2. Bericht an das Bundesministerium für Gesundheit über die Zulassung von Cerivastatin-haltigen Arzneimitteln (Lipobay, Zenas, Vazqol) und die nachfolgende Sicherheitsüberwachung. August 2001.
3. Bischoff H, Heller AH: Preclinical and clinical pharmacology of cerivastatin. Am J Cardiol 1998;82:18J-25J. Review.
4. Bolego C, Baetta R, Bellosta S, Corsini A, Paoletti R: Safety considerations for statins. Curr Opin Lipidol 2002;13:637-644.
5. Bottorff M, Hansten P: Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians. Arch Intern Med 2000:160:2273-2278. Review.
6. Brown MS, Goldstein JL: Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 1980;21:505-517. Review.
7. Dansette PM, Jaoen M, Pons C: HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins. Exp Toxicol Pathol 2000;52:145-148.
8. Downs JR, Clearfield M, Tyroler HA, Whitney EJ, Kruyer W, Langendorfer A, Zagrebelsky V, Weis S, Shapiro DR, Beere PA, Gotto AM: Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 2001;87:1074-1079.
9. Farmer JA, Torre-Amione G: Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf. 2000;23:197-213. Review.
10. Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ. Tamagawa H: Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A. 1990;87:8931-8934.
11. Freemantle N, Hill S: Medicalisation, limits to medicine, or never enough money to go around? BMJ 2002;324:864-865.
12. Furberg CD, Pitt B: Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001:2:205-207.
13. Gaist D, Rodriguez LA, Huerta C, Hallas J, Sindrup SH: Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001;12:565-569.
14. Gibaldi M: Pharmacokinetic variability-drug interactions. Biopharmaceutics and clinical pharmacokinetics. 4th edition. Philadelphia, Lea & Febiger. 1991.
15. Glossmann H: Cerivastatin (Lipobay®, Baycol®) and the ABC of pharmacokinetics and pharmacodynamics, http://bmj.com/cgi/eletters/ 323/7309/359/a#16270, Aug 2001.
16. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature. 1990:343:425-430. Review.
17. Goli AK, Goli SA, Byrd RP Jr, Roy TM: Simvastatin-induced lactic acidosis: a rare adverse reaction? Clin Pharmacol Ther 2002;72:461-464.
18. Guengerich FP: Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1-17. Review.
19. Hamelin BA, Turgeon J: Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998;19:26-37, Review.
20. Hamilton-Craig I: Statin-associated myopathy. Med J Aus. 2001 Nov;175:486-489. Review.
21. Igel M, Sudhop T, von Bergmann K: Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001;57:357-364. Review.
22. Isaacsohn J, Insull W Jr, Stein E, Kwiterovich P, Patrick MA, Brazg R, Dujovne CA, Shan M, Shugrue-Crowley E, Ripa S, Tota R: The Cerivastatin Study Group: Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia. Clin Cardiol 2001;24(9 Suppl):IV1-9.
23. Kaneider NC, Reinisch CM, Dunzendorfer S, Meierhofer C, Djanani A, Wiedermann CJ: Induction of apoptosis and inhibition of migration of inflammatory and vascular wall cells by cerivastatin. Atherosclerosis 2001;158:23-33.
24. Kostner GM: Pharmacology of HMG CoA reductase inhibitors (statins) Wien Med Wochenschr 1999;149:120-4. Review.
25. Kostner KM, Kostner GM: Lowering cholesterol 1998. Cholesterol synthesis inhibitors compared. Wien Klin Wochenschr 1998:110:625-630. Review.
26. Laaksonen R, Ojala JP, Tikkanen MJ, Himberg JJ: Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1994:46:313-317.
27. Lucas RA, Weathersby BB, Rocco VK, Pepper JM, Butler KL: Rhabdomyolysis associated with cerivastatin: six cases within 3 months at one hospital. Pharmacotherapy 2002;22:771-774.
28. Mortensen SA, Leth A, Agner E, Rohde M: Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 1997;18(Suppl):137-144.
29. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
30. Mück W: Clinical pharmacokinetics of cerivastatin. Clin Pharmacokinet 2000;39:99-116.
31. Ogasahara S, Engel AG, Frens D, Mack D: Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci USA. 1989;86:2379-2382.
32. Paoletti R, Corsini A, Bellosta S: Pharmacological interactions of statins. Atheroscler Suppl 200;3:35-40. Review.
33. Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, Miettinen T, Musliner TA, Olsson AG, Pyorala K, Thorgeirsson G, Tobert JA, Wedel H, Wilhelmsen L: Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996:156:2085-2092.
34. Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, Liu L, Lin JH, Pearson PG. Baillie TA: Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002;301:1042-1051.
35. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994:344:1383-1389.
36. Rosenson RS, Tangney CC: Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:1643-1650. Review.
37. Scott HD, Thacher-Renshaw A, Rosenbaum SE, Waters WJ Jr, Green M, Andrews LG, Faich GA: Physician reporting of adverse drug reactions. Results of the Rhode Island Adverse Drug Reaction Reporting Project. JAMA 1990:263:1785-1788.
38. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995:333:1301-1307.
39. Sinzinger H, Wolfram R, Peskar BA: Muscular side effects of statins. J Cardiovasc Pharmacol 2002;40:163-171.
40. Sinzinger H: Side effects of Statins - prevalence, relevance, consequences. Wien Klin Wochenschr 2002;114:887-888.
41. Staffa JA, Chang J, Green L: Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002;346:539-540.
42. Stein E, Isaacsohn J, Stoltz R, Mazzu A, Liu MC, Lane C, Heller AH: Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia. Am J Cardiol 1999:83:1433-1436.
43. Thibault A, Samid D, Tompkins AC, Figg WD. Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE: Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res, 1996;2:483-491.
44. Watts GF, Castelluccio C, Rice-Evans C, Taub NA, Baum H, Quinn PJ: Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 1993;46:1055-1057.
45. Wong WW, Tan MM, Xia Z, Dimitroulakos J, Minden MD. Penn LZ: Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res 2001;7:2067-2075.